40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
View analysts' price targets and recommendations, and compare them with competitors.
$52.00
Lower upside than AR's upside of 54.83%.
Buy
Equal to AR's analyst recommendation of Buy.
Analyze analyst forecasts for the company and compare them with competitors.
2.89B
The estimated revenue has decreased from the previous period.
-2.66B
The estimated EBITDA has increased from the previous period.
0.18
The estimated EPS has increased from the previous period.
-1.81B
The estimated net income has increased from the previous period.
-1.26B
The estimated EBIT has decreased from the previous period.
608.94M
The estimated SG&A expenses have decreased from the previous period.
Analyze DCF forecasts for the company and compare them with competitors.
19.01B
Revenue has increased from the previous period.
15.56%
Revenue growth rate is unchanged from the previous period.
3.80B
EBITDA has increased from the previous period.
20.00%
EBITDA margin is unchanged from the previous period.
-57.36M
EBIT has decreased from the previous period.
-0.30%
EBIT margin is unchanged from the previous period.
3.86B
Depreciation has increased from the previous period.
201.88M
Total cash has increased from the previous period.
1.06%
Cash percentage is unchanged from the previous period.
2.70B
Receivables have increased from the previous period.
14.23%
Receivables percentage is unchanged from the previous period.
22.28M
Inventories have increased from the previous period.
0.12%
Inventory percentage is unchanged from the previous period.
873.88M
Accounts payable has increased from the previous period.
4.60%
Payables percentage is unchanged from the previous period.
-4.77B
Capital expenditure has increased from the previous period.
-25.11%
CapEx percentage is unchanged from the previous period.
12.06%
WACC is unchanged from the previous period.
16.87%
Cost of equity is unchanged from the previous period.
5.31%
Cost of debt is unchanged from the previous period.
2.64
Beta is unchanged from the previous period.
263.90M
Diluted shares outstanding is unchanged from the previous period.
6.68B
Total debt is unchanged from the previous period.
10.03B
Total equity is unchanged from the previous period.
16.71B
Total capital is unchanged from the previous period.
39.98%
Debt weighting is unchanged from the previous period.
60.02%
Equity weighting is unchanged from the previous period.
-52.47M
EBIAT has decreased from the previous period.
-1.22B
UFCF has decreased from the previous period.
0.50%
Long-term growth rate is unchanged from the previous period.
-12.22B
Terminal value is unchanged from the previous period.
-10.90B
Enterprise value is unchanged from the previous period.
6.68B
Net debt is unchanged from the previous period.
-17.58B
Equity value is unchanged from the previous period.
-66.63
Equity value per share is unchanged from the previous period.
